• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
TP53 immunohistochemistry correlates with mutation status and clearance in decitabine-treated patients with myeloid malignancies.TP53免疫组化与地西他滨治疗的髓系恶性肿瘤患者的突变状态及清除情况相关。
Haematologica. 2019 Aug;104(8):e345-e348. doi: 10.3324/haematol.2018.205302. Epub 2019 Feb 21.
2
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
3
Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.地西他滨：一种治疗骨髓增生异常综合征和急性髓系白血病的有效且安全的疗法。
J Cancer Res Ther. 2019;15(7):1471-1476. doi: 10.4103/0973-1482.204849.
4
Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.地西他滨可改善年龄≥60 岁骨髓增生异常综合征-RAEB 患者的总生存，且毒性更低：与低剂量化疗的比较。
Blood Cells Mol Dis. 2019 Jul;77:88-94. doi: 10.1016/j.bcmd.2019.03.010. Epub 2019 Mar 31.
5
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.TP53 突变型急性髓系白血病采用低强度治疗的结果。
Leuk Lymphoma. 2018 Sep;59(9):2238-2241. doi: 10.1080/10428194.2017.1422864. Epub 2018 Jan 17.
6
New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine.
Future Oncol. 2021 Jun;17(16):1973-1975. doi: 10.2217/fon-2021-0220. Epub 2021 Apr 21.
7
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.TP53 基因突变可预测去甲基化药物地西他滨治疗骨髓增生异常综合征患者的完全缓解。
Br J Haematol. 2017 Feb;176(4):600-608. doi: 10.1111/bjh.14455. Epub 2016 Dec 16.
8
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.甲基化抑制剂治疗的骨髓增生异常综合征中TP53突变的临床意义
Oncotarget. 2016 Mar 22;7(12):14172-87. doi: 10.18632/oncotarget.7290.
9
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.治疗相关髓系肿瘤中高 p53 蛋白表达与不良核型和预后不良相关。
Mod Pathol. 2015 Apr;28(4):552-63. doi: 10.1038/modpathol.2014.153. Epub 2014 Nov 21.
10
Monoclonal Gammopathy Responsive to Decitabine Given for Acute Myeloid Leukemia in a Frail Patient.地西他滨治疗老年急性髓系白血病患者时出现反应性单克隆丙种球蛋白病
Acta Haematol. 2018;139(1):58-59. doi: 10.1159/000485960. Epub 2018 Jan 17.

引用本文的文献

1
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.使用质谱流式细胞术进行的T细胞免疫聚类分析可识别急性髓系白血病患者的独特亚组。
Blood Adv. 2025 Jan 28;9(2):239-243. doi: 10.1182/bloodadvances.2024014553.
2
A line in shifting sand: Can we define and target TP53 mutated MDS?流沙中的一条线：我们能否定义并靶向 TP53 突变的骨髓增生异常综合征？
Semin Hematol. 2024 Dec;61(6):449-456. doi: 10.1053/j.seminhematol.2024.10.009. Epub 2024 Nov 6.
3
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.从血液系统恶性肿瘤中p53的调控到去调控：对诊断、预后和治疗的影响
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
4
TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.髓系肿瘤中 TP53 基因突变：对准确的实验室检测、诊断和治疗的影响。
Lab Med. 2024 Nov 4;55(6):686-699. doi: 10.1093/labmed/lmae048.
5
Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation.复发性口咽鳞状细胞癌在完成放疗后仍保持抗肿瘤免疫和多核水平。
Head Neck Pathol. 2023 Dec;17(4):952-960. doi: 10.1007/s12105-023-01597-z. Epub 2023 Nov 23.
6
The Pathology according to p53 Pathway.根据 p53 通路的病理学。
Pathobiology. 2024;91(3):230-243. doi: 10.1159/000535203. Epub 2023 Nov 14.
7
Utilizing digital pathology and immunohistochemistry of p53 as an adjunct to molecular testing in myeloid disorders.利用数字病理学和p53免疫组织化学作为骨髓疾病分子检测的辅助手段。
Acad Pathol. 2023 Feb 1;10(1):100064. doi: 10.1016/j.acpath.2022.100064. eCollection 2023 Jan-Mar.
8
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.来那度胺治疗多发性骨髓瘤后出现的 B-ALL 具有独特的克隆特征。
Blood Adv. 2023 Jan 24;7(2):236-245. doi: 10.1182/bloodadvances.2022007496.
9
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.基因组分析在髓系肿瘤和急性白血病中的临床决策应用。
Blood. 2022 Nov 24;140(21):2228-2247. doi: 10.1182/blood.2022015853.
10
Pure erythroid leukemia is characterized by biallelic inactivation and abnormal p53 expression patterns in and secondary cases.纯红细胞白血病的特征是双等位基因失活以及原发性和继发性病例中p53表达模式异常。
Haematologica. 2022 Sep 1;107(9):2232-2237. doi: 10.3324/haematol.2021.280487.

本文引用的文献

1
Mutation Clearance after Transplantation for Myelodysplastic Syndrome.骨髓增生异常综合征患者移植后的基因突变清除
N Engl J Med. 2018 Sep 13;379(11):1028-1041. doi: 10.1056/NEJMoa1804714.
2
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
3
Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.p53免疫组织化学是一种有用的工具，可用于识别伴有骨髓发育异常相关改变、TP53突变、核型复杂且预后不良的急性髓系白血病病例。
Mod Pathol. 2017 Mar;30(3):382-392. doi: 10.1038/modpathol.2016.206. Epub 2016 Dec 9.
4
Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.p53的免疫组织化学模式是骨髓增生异常综合征和继发性急性髓系白血病中TP53突变负荷及不良临床结局的一项指标。
Haematologica. 2016 Aug;101(8):e320-3. doi: 10.3324/haematol.2016.143214. Epub 2016 Apr 14.
5
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).p53蛋白表达可独立预测伴有5号染色体长臂缺失（del(5q)）的低危骨髓增生异常综合征患者的预后。
Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28.
6
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.成人新发急性髓系白血病的基因组和表观基因组图谱。
N Engl J Med. 2013 May 30;368(22):2059-74. doi: 10.1056/NEJMoa1301689. Epub 2013 May 1.
7
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.骨髓增生异常综合征中的 TP53 突变与 5 号染色体异常密切相关，并与不良预后相关。
Br J Haematol. 2013 Mar;160(5):660-72. doi: 10.1111/bjh.12203. Epub 2013 Jan 9.
8
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.急性髓系白血病伴复杂核型中 TP53 改变与特定拷贝数改变、单体核型和不良预后相关。
Blood. 2012 Mar 1;119(9):2114-21. doi: 10.1182/blood-2011-08-375758. Epub 2011 Dec 20.
9
Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue.免疫组织化学检测福尔马林固定石蜡包埋组织中蛋白质时分析前变量的影响。
Arch Pathol Lab Med. 2011 May;135(5):537-43. doi: 10.5858/2010-0702-RAIR.1.
10
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.10 天疗程地西他滨治疗老年 AML 患者的临床反应及 miR-29b 的预测意义。
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. doi: 10.1073/pnas.1002650107. Epub 2010 Apr 5.

TP53 immunohistochemistry correlates with mutation status and clearance in decitabine-treated patients with myeloid malignancies.

作者信息

Ruzinova Marianna B, Lee Yi-Shan, Duncavage Eric J, Welch John S

机构信息

Department of Pathology and Immunology.

Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA

出版信息

Haematologica. 2019 Aug;104(8):e345-e348. doi: 10.3324/haematol.2018.205302. Epub 2019 Feb 21.

DOI:10.3324/haematol.2018.205302
PMID:30792212
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6669137/
Abstract
摘要